Lonza and NeuroSense Therapeutics Ltd., a company developing treatments for amyotrophic lateral sclerosis (ALS) and other severe neurodegenerative diseases, have entered a collaboration to evaluate biological changes occurring in people with neurodegenerative diseases, including ALS.     This agreement provides NeuroSense with access to Lonza’s state-of-the-art extracellular vesicles expertise and capabilities quickly and on an ‘on-demand’ basis, without further commitments. NeuroSense ...